Insitro

Insitro

A bioinformatics company in San Francisco building data collection methods and databases that will enable machine learning algorithms in healthcare. It was founded in 2018.

About

Insitro is a San Francisco-based biotechnology company with a focus on using artificial intelligence and other technologies for the research and development of drugs for medical patients. It uses machine learning and high-throughput biology to develop its therapeutics.

Product

The company has developed predictive models which are intended to be used to provide insight into which drugs will be successful and for which group of people. These models use information from patients such as genetic, phenotypic, and clinical data to conduct analyses. It uses the results from these analyses to create cell-based disease models. Machine learning is applied in order to differentiate between cell states. The use of in vitro models of disease combined with in silico machine learning models is where the name of the company, insitro, derives. The company uses these technologies to make predictions about interventions that may work for the diseases,

Insitro's technology has been used to research and develop drugs for diseases such as non-alcoholic fatty liver disease. It can also be used to discover subtypes of diseases, such as Alzheimer's and diabetes.

Timeline

May 2020

Insitro raises a $143,210,951 series B round from Third Rock Ventures, Andreessen Horowitz, HOF Capital, ARCH Venture Partners, Casdin Capital, Foresite Capital, BlackRock, Alexandria Venture Investments, Canada Pension Plan Investment Board, Two Sigma Ventures, T. Rowe Price and GV.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Daphne Koller

Founder

Further reading

Title
Author
Link
Type
Date

Combining AI and biology could solve drug discovery's biggest problems

Ruth Reader

Web

June 14, 2020

insitro Announces $143 Million Raised in Series B Financing

Web

May 26, 2020

Documentaries, videos and podcasts

Title
Date
Link

AWS re:Invent 2019 - Daphne Koller of insitro Talks About Using AWS to Transform Drug Development

December 16, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Krystle Vermes
May 26, 2020
BioSpace
The funding will be used to continue to build the company's technology and automation, which enable data generation at a larger scale. This will expand Insitro's ability to create predictive models of human disease.
Amirah Al Idrus
May 26, 2020
FierceBiotech
In the two years since it set up shop, insitro has been plugging away at a data- and machine learning-driven approach to drug discovery. Now, the company is picking up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.